Join us March 10 for the Hepatitis B Foundation Gala <<Click here>>

Welcome to Hepatitis Delta Connect!

A dedicated program of the Hepatitis B Foundation to increase awareness about hepatitis delta - a serious virus that coinfects hepatitis B patients - and to promote screening and testing, and provide information and support for those affected. 

Copy of Website transmission graphic asian african blended

    Clinical Trial Finder - Find A Clinical Trial Near You! 

          hepbfoundation hepdelta banner 2            

Check Out Our Latest Podcast!

Spotlight on Stigma2

Join us for a podcast in which researchers from the Hepatitis B Foundation in the United States and the University of New South Wales in Australia come together to discuss the profound impacts stigma can have on the lives of people living with hepatitis B. Click here to listen today!

Check Out Our Latest Webinar!

Recordings Available FBIG

In Case You Missed It... Catch the recording of "The Lived Experience of Hepatitis Delta" webinar here!

Hear real-world HDV perspectives from people around the globe who have been personally affected by hepatitis delta. The featured speakers are Basu Lkhagvasuren, Ibrahima Gueye, Danielle Raphael and, Lori Scott. They share insights about their experiences, and speak specifically to their navigation of hepatitis delta diagnosis, treatment, and management, and the effects that the virus has had on their lives.

New Podcast on Hepatitis Delta

Podcast Branding Templates IG FB 7 1

Listen to the latest episode of B Heppy, the Hepatitis B Foundation's monthly podcast, all about hepatitis delta! B Heppy host Evangeline chats with Dr. Robert Gish to discuss what hepatitis delta is, how it is related to hepatitis B, how to manage it, and what future treatment options look like. Click here to listen today!

Hep Delta Patient and Provider Surveys FB IG

We would love to hear from you! Complete the survey to sign upPlease note: This survey link is specifically for those living with hepatitis delta, or those who are caretakers of people living with hepatitis delta.

Hep Delta Patient and Provider Surveys FB IG 3

Take our brief survey & sign up to receive updates on clinical trials, info about hepatitis delta monitoring, management & care + more! Sign up today! Please note: This survey link is specifically for healthcare providers caring for people living with hepatitis delta.

Am i at risk
Newly Diagnosed png

Website map by users2

We've educated 13,000 people in 111 countries!


News & Updates

September 2022 Blog Post: What's the Difference? Herbal Remedies and Supplements vs. Western Medicine

July 2022 Blog Post: Results from Hepatitis Delta Clinical Trials Announced at 2022 International Liver Congress

May 2022 Blog Post: Roundtable Discussion Highlights Hepatitis Delta

February 2022 Blog Post: 2022 - The Year of Hepatitis Delta

View our webinar, Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies? recording here.

01/21/2023: Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
01/11/2023: Identifying and Screening At-Risk Patients for Hepatitis Delta Virus: A Case Report
01/2023: D is for Diagnosis, Whom to Screen for hepatitis Delta virus
12/2022: Low Performance of Hepatitis Delta Virus Testing Among 2 National Cohorts of Chronic Hepatitis B Patients in the United States
12/8/2022: Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
11/12/2022: Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks
11/11/2022: Bulevirtide Improves Health-Related Quality of Life (Phase 3 Clinical Trial Presentation at AASLD)
11/04/2022: Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
10/27/2022: Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus. 
Gilead is discussing with the FDA to get bulevirtide approved in the US and bring the treatment to people living with HDV. Global advocates are still fighting for widespread access to effective hepatitis delta treatments.
10/27/2022: COVID-19 Impacts HDV Screening, Patient Outcomes
10/17/2022: Identification of a novel interaction site between the large hepatitis delta antigen and clathrin that regulates the assembly of genotype III hepatitis delta virus
09/2022: Presentation from International HBV Meeting: Combined results from the clinical trials MYR203 and MYR301, in patients with chronic hepatitis D
09/25/2022: Replicor Inc. has updated clinical data on the compassionate use program for treating chronic HBV/HDV co-infection in cirrhotic patients
09/22/2022: Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
09/13/2022: Phase 2 Trial Study: Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus & hepatitis D virus coinfection
09/2022: Diagnosing and Screening for Hepatitis D Viral Infection
06/2022: EASL Presentation - Peginterferon Lambda (IFN-λ) combined with Lonafarnib diminished triphasic HDV kinetic pattern seen under IFN-λ monotherapy: The LIFT-1 Study
06/2022: EASL Presentation - Mathematical modeling of HDV RNA kinetics suggests high peginterferon lambda efficacy in blocking viral production: Insights from the LIMT-1 study
06/2022: EASL Presentation - Rising Clinical and Economic Burden Among Hepatitis D Patients Who Attended Spanish Hospitals
06/2022: EASL Presentation - Provider Factors Shaping Hepatitis Delta Screening
06/2022: EASL Presentation - Hepatitis delta virus reflex testing in patients with hepatitis B dramatically improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France
06/27/22: Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2022
06/27/22: Vir Biotechnology Inc. Announces New Clinical Data from Its Broad Hepatitis B Program
06/23/22: Treatment with Hepcludex (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
06/16/22: Review Shines a Light on the Overlooked Virus, Hepatitis D
06/08/22: Eiger BioPharma Announces Multiple Presentations at EASL's International Liver Congress 2022
05/12/2022: Research Article Examining the Different Evolutionary Dynamics of the hepatitis B and hepatitis D virus
04/27/2022: Vir Biotechnology Unveils New Plans for Hepatitis D Treatment
Get Connected

square facebook 512Twitter icon horizontal2instagram icon

Contact us button2